RG203KR Mutations in SARS-CoV-2 Nucleocapsid: Assessing the Impact Using a Virus-Like Particle Model System
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Since its origin in late 2019, the SARS-CoV-2 virus has been constantly mutating and evolving. Current studies mostly employ spike protein (S) pseudovirus systems to determine the effects of mutations on the infectivity and immunogenicity of variants.
Article activity feed
-
-
SciScore for 10.1101/2022.01.02.473343: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IACUC: Animal immunization: Approval for animal experiments was taken from ‘Institutional Animal Ethics Committee’. Sex as a biological variable 24 female BALB/c mice, 6 weeks old, were grouped into four groups and immunization was given intra peritoneal (i.p.). Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources After permeabilization by 0.1 % Triton X-100 for 2 min at room temperature, cells were incubated with 3 % BSA at 37 °C for 1 h followed by incubation with the indicated antibody for 2 h at 4 °C and then detected by Alexa-633-conjugated anti-mouse or Alexa-488 conjugated anti-rabbit … SciScore for 10.1101/2022.01.02.473343: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IACUC: Animal immunization: Approval for animal experiments was taken from ‘Institutional Animal Ethics Committee’. Sex as a biological variable 24 female BALB/c mice, 6 weeks old, were grouped into four groups and immunization was given intra peritoneal (i.p.). Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources After permeabilization by 0.1 % Triton X-100 for 2 min at room temperature, cells were incubated with 3 % BSA at 37 °C for 1 h followed by incubation with the indicated antibody for 2 h at 4 °C and then detected by Alexa-633-conjugated anti-mouse or Alexa-488 conjugated anti-rabbit secondary antibody for 30 min (Invitrogen). anti-mousesuggested: Noneanti-rabbitsuggested: NoneSamples were then analyzed by western blot using the desired antibodies, anti-SARS-CoV-2 S protein (Cat. No.-40591-T62), anti-SARS-CoV-2 N protein (Cat. No.-40143-MM05) anti-SARS-CoV-2 S proteinsuggested: Noneanti-SARS-CoV-2 N proteinsuggested: None, Immunized mice sera followed by the respective secondary antibodies (horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG; Sigma). anti-rabbit IgGsuggested: NoneExperimental Models: Cell Lines Sentences Resources Isolation of VLP: The Baculovirus infected Sf21 cells were lysed with TEN buffer [10 mM Tris (pH 7.5), 1.0 mM EDTA, 1.0 M NaCl, 0.1% Triton X100, 1 mM PMSF]. Sf21suggested: NoneVero cells (5×105) were added to the mixture of SARS-CoV-2-VLPs and antibody in DMEM and 25 mM of HEPES buffer (100 µl) and incubated for 2 h at room temperature. Verosuggested: NoneExperimental Models: Organisms/Strains Sentences Resources 24 female BALB/c mice, 6 weeks old, were grouped into four groups and immunization was given intra peritoneal (i.p.). BALB/csuggested: RRID:IMSR_ORNL:BALB/cRl)Recombinant DNA Sentences Resources Vector DNA pBacPAK9 containing the target gene was transfected into Spodoptera frugiperda cells, along with Bsu36 I-digested BacPAK6 Viral DNA as described earlier (Takara Bio Inc., USA). pBacPAK9suggested: NoneSoftware and Algorithms Sentences Resources Images were taken using Zeiss microscope and image analysis was done using the Zeiss LSM or ZEN software tools. ZENsuggested: NoneStatistical analyses were performed using Graph Pad Prism version 8.0. Graph Pad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 9. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-